Toll-Like Receptor 7 Staining in Malignant Epithelial Tumors

被引:1
作者
Franz, Regina [1 ]
Ritter, Nathalie [1 ]
Hein, Ruediger [1 ]
Biedermann, Tilo [1 ]
Al-Sisi, Mohammed [1 ]
Eyerich, Kilian [1 ]
Garzorz-Stark, Natalie [1 ]
Andres, Christian [1 ,2 ]
机构
[1] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany
[2] Labor Dermatohistol, Sonnenstr 7, D-80331 Munich, Germany
基金
欧盟地平线“2020”;
关键词
Toll-like receptor 7; squamous cell carcinoma; basal cell carcinoma; basosquamous carcinoma; SQUAMOUS-CELL CARCINOMA; IMIQUIMOD; AGONIST; CANCER;
D O I
10.1097/DAD.0000000000000784
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: As important players of the innate immune system, Toll-like receptors (TLRs) and their role for tumorigenesis have been in the focus of research. In particular TLR7 is an interesting candidate, as TLR7 agonists are broadly used for the treatment of cutaneous tumors. However, data addressing the baseline expression of TLR7 in both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) on the protein level are lacking, while on the genomic level significantly elevated expression of TLR7 in SCC but not in BCC has been demonstrated. Aim: Our aim was to characterize the immunohistochemical staining pattern of TLR7 in SCC and BCC. Besides, we aimed to clarify if, in case of different TLR7 expression between SCC and BCC, TLR7 expression would help to define basosquamous carcinoma (BSC), a tumor entity sharing characteristics of both SCC and BCC. Methods: We examined histopathological samples from 23 BCC, 4 BSC, and 24 SCC and characterized the expression of TLR7 by immunohistochemistry and immunofluorescence. Results: We found that TLR7 was not expressed by the tumor tissue of SCC, BCC, and BSC, but by inflammatory cells located within the tumoral and/or peritumoral tissue. Whereas the overall expression of TLR7 did not differ between BCC and SCC (30.4% vs. 45.8%, respectively), we found that within the group of SCC, the well-differentiated SCC showed strong tumoral and/or peritumoral immunocellular TLR7 reactivity in contrast to the poorly differentiated SCC (73.33% vs. 11.1%, respectively). Besides, immunofluorescence double staining revealed the expression of TLR7 in immune cells closely interacting with T cells and natural killer cells. Conclusions: In contrast to genomic data, we did not find a general difference between baseline TLR7 expression of SCC and BCC on the protein level. Nevertheless, the expression of TLR7 by the inflammatory infiltrate associated with SCC may correlate with the degree of differentiation of SCC possibly indicating better outcome.
引用
收藏
页码:742 / 746
页数:5
相关论文
共 50 条
[41]   Toll-like receptors involved in the response to microbial pathogens: Development of agonists for toll-like receptor 9 [J].
Schetter, C ;
Vollmer, J .
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (02) :204-210
[42]   Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands [J].
Rostamizadeh, Leila ;
Molavi, Ommoleila ;
Rashid, Mohsen ;
Ramazani, Fatemeh ;
Baradaran, Behzad ;
Lavasanaifar, Afsaneh ;
Lai, Raymond .
BIOIMPACTS, 2022, 12 (03) :261-290
[43]   Toll-like receptor-targeted anti-tumor therapies: Advances and challenges [J].
Yang, Yang ;
Li, Hongyi ;
Fotopoulou, Christina ;
Cunnea, Paula ;
Zhao, Xia .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[44]   Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle [J].
Ekman, Anna-Karin ;
Adner, Mikael ;
Cardell, Lars-Olaf .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 652 (1-3) :145-151
[45]   Toll-like receptor 7-mediated enhancement of contextual fear memory in mice [J].
Kubo, Yasunori ;
Yanagawa, Yoshiki ;
Matsumoto, Machiko ;
Hiraide, Sachiko ;
Kobayashi, Masanobu ;
Togashi, Hiroko .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 102 (04) :495-501
[46]   Effect of activation of Toll-like receptor 7 in the inhibition of allergic asthma on a mouse model [J].
Ma, Li ;
Xiao, Xiaojun ;
Ma, Yihe ;
Wu, Haiqiang ;
Qiu, Shuqi ;
Li, Jing ;
Yang, Pingchang ;
Liu, Zhigang .
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (05) :2143-2152
[47]   Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics [J].
Huang, Xuan ;
Zhang, Xiaoyong ;
Lu, Mengji .
EXPERT OPINION ON DRUG DISCOVERY, 2021, 16 (08) :869-880
[48]   Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer [J].
Rolfo, Christian ;
Giovannetti, Elisa ;
Martinez, Pablo ;
McCue, Shannon ;
Naing, Aung .
NPJ PRECISION ONCOLOGY, 2023, 7 (01)
[49]   Galloylated Toll-Like Receptor 7/8 Agonist Nanovaccine for Enhanced Tumor Antigen Delivery in Personalized Immunotherapy [J].
Ma, Mengyao ;
Li, Ximu ;
Zhong, Mingyuan ;
Li, Xuejing ;
Yu, Jiang ;
Wang, Zhaomeng ;
Lv, Qingzhi ;
Li, Xin ;
He, Zhonggui ;
Liu, Hongzhuo ;
Wang, Yongjun .
ACS NANO, 2025, 19 (12) :11900-11912
[50]   Toll-like receptor 9 expression in the natural history of Barrett mucosa [J].
Huhta, Heikki ;
Helminen, Olli ;
Kauppila, Joonas H. ;
Takala, Heikki ;
Metsikko, Kalervo ;
Lehenkari, Petri ;
Saarnio, Juha ;
Karttunen, Tuomo .
VIRCHOWS ARCHIV, 2015, 467 (01) :9-18